Tirzepatide is the best obesity drug currently approved. It produced 20.9% mean weight loss at 72 weeks in SURMOUNT-1 (Jastreboff et al. 2022 NEJM), beating every prior medication and approaching the weight loss seen with sleeve gastrectomy.<\/p>\n
Retatrutide may displace it. The phase 2 trial of retatrutide (Jastreboff et al. 2023 NEJM) produced 24.2% mean weight loss at 48 weeks, with the highest-responding patients losing more than 30%. Phase 3 trials are running, and an FDA submission is expected in late 2026 or 2027 if the data hold up.<\/p>\n
This comparison is partly about today (tirzepatide is available now; retatrutide isn’t) and partly about what the next 18 to 24 months may bring. Understanding the difference helps you make sense of the news cycle and plan a treatment trajectory.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
Tirzepatide is a dual agonist.<\/strong> It activates the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Both receptors are involved in appetite, satiety, and glucose metabolism. The combination produces stronger weight loss than GLP-1 agonism alone, as seen in SURMOUNT-5 against semaglutide.<\/p>\n Quick Answer: Tirzepatide is a dual GLP-1 and GIP receptor agonist, FDA-approved as Mounjaro\u00ae (diabetes) and Zepbound\u00ae (obesity)<\/p>\n Retatrutide is a triple agonist. It activates GLP-1, GIP, and glucagon receptors. Glucagon agonism is the new piece. Glucagon traditionally is known as the hormone that raises blood sugar by stimulating glucose release from the liver. But glucagon also increases energy expenditure, stimulates fat oxidation, and reduces appetite through central pathways.<\/p>\n The bet on glucagon agonism is that adding it to GLP-1 and GIP produces additional weight loss through a different mechanism (increased calorie burning) than what GLP-1 and GIP provide (reduced calorie intake). The phase 2 data supports that bet.<\/p>\n The phase 2 trial (Jastreboff et al.<\/strong> 2023 NEJM) tested retatrutide at four doses against placebo in 338 adults with obesity over 48 weeks. The results were striking. At the 12 mg dose (the highest tested), mean weight loss was 24.2%. At 8 mg, 22.8%. At 4 mg, 17.5%. At 1 mg, 8.7%.<\/p>\n The weight loss curve hadn’t plateaued at 48 weeks. The proportion of patients losing at least 25% of body weight was 36% at the highest dose. At least 15% loss: 83%.<\/p>\n These numbers exceeded tirzepatide’s SURMOUNT-1 results, though direct comparison requires caution because the trial designs and patient populations differed slightly.<\/p>\n Phase 3 trials began in 2023 under the TRIUMPH program.<\/strong> TRIUMPH-1 (obesity), TRIUMPH-2 (obesity + cardiovascular risk), TRIUMPH-3 (obesity + cardiovascular disease), and TRIUMPH-4 (obesity + osteoarthritis) are ongoing. Top-line readouts began in late 2025 and continue through 2026.<\/p>\n Assuming positive phase 3 data, Eli Lilly is expected to submit to the FDA in late 2026 or 2027. FDA approval, if granted, would likely come 9 to 12 months after submission, putting potential availability in late 2027 or 2028.<\/p>\n These dates can shift. Phase 3 trials sometimes produce slower-than-expected results or new safety signals. Until phase 3 data is published and FDA review completes, retatrutide’s timeline is provisional.<\/p>\n The phase 2 retatrutide trial showed a similar GI side effect profile to other GLP-1-based drugs: nausea, vomiting, diarrhea, constipation, most common during dose escalation.<\/strong> The rates appeared dose-dependent and generally comparable to tirzepatide at similar effective doses.<\/p>\n One additional finding from the phase 2 trial: dose-dependent increases in heart rate (roughly 5 to 10 bpm at the highest doses), thought to be linked to glucagon receptor activation. The clinical significance of this in long-term use is still being characterized in phase 3.<\/p>\n Glucagon agonism also raises a theoretical concern about glucose control. Glucagon raises blood sugar, so a glucagon agonist could worsen diabetes. The phase 2 data actually showed glucose improvement in patients with diabetes, suggesting the GLP-1 and GIP effects dominate the glucagon effect for net glycemic control. Phase 3 in diabetic populations is testing this more rigorously.<\/p>\n Tirzepatide is a weekly subcutaneous injection titrated every 4 weeks from 2.5 mg up to 15 mg, total titration over 20 weeks.<\/strong><\/p>\n Retatrutide in phase 2 was also weekly subcutaneous, titrated up to 12 mg over 12 to 16 weeks depending on the arm. The final approved dosing schedule will be set by phase 3 results and FDA review.<\/p>\n Both drugs follow the now-standard pattern of slow titration to manage GI side effects.<\/p>\n Key Takeaway: Tirzepatide produced 20.9% weight loss at 72 weeks in SURMOUNT-1; retatrutide produced 24.2% at 48 weeks in phase 2<\/p>\n Tirzepatide brand pricing in 2026: Zepbound lists at around $1,086\/month.<\/strong> Lilly’s LillyDirect cash program offers single-dose vials at $349 to $499\/month. Compounded tirzepatide through telehealth platforms like TrimRx typically runs $200 to $500\/month, though the FDA’s removal of tirzepatide from the shortage list in late 2024 has restricted compounding eligibility for many patients.<\/p>\n Retatrutide isn’t available outside of clinical trials. When approved, pricing is likely to start at or above current brand obesity drug levels, given the typical pattern for newer drugs. Insurance coverage and direct cash programs will probably follow several years after launch, mirroring how Zepbound and Wegovy\u00ae have evolved.<\/p>\n For most patients, no.<\/strong> Tirzepatide is available now and produces excellent results. Waiting 2 to 3 years for retatrutide while staying overweight or obese isn’t a good trade. The cardiovascular, kidney, sleep apnea, and other outcome benefits of available GLP-1s compound over time.<\/p>\n For specific patients, the wait might make sense. Those with severe class III obesity (BMI 50+) who might benefit from retatrutide’s stronger effect, patients who’ve already plateaued on tirzepatide at maximum dose, and those weighing surgery as the alternative might reasonably wait if the FDA timeline holds.<\/p>\n For most patients with substantial obesity now, starting tirzepatide or semaglutide now and switching to retatrutide later if it becomes available and clinically indicated is the better play.<\/p>\n We don’t know yet. The phase 2 trial wasn’t sized or designed for outcomes like cardiovascular events, kidney function, or sleep apnea. The TRIUMPH-2 and TRIUMPH-3 trials will provide more cardiovascular data, but full outcome trials specifically powered for MACE will take longer.<\/p>\n Tirzepatide has the SURMOUNT trial data including SURMOUNT-OSA (FDA-approved for sleep apnea), but lacks a published cardiovascular outcome trial in the obesity population. Semaglutide remains the GLP-1 with the strongest evidence base for cardiovascular and kidney outcomes (SELECT and FLOW).<\/p>\n Bottom line: Retatrutide isn’t FDA-approved yet; expected submission late 2026 or 2027<\/p>\n Outside of enrolled clinical trials, no. Retatrutide isn’t FDA-approved and shouldn’t be available through legitimate pharmacies or compounding services. Any source claiming to provide retatrutide commercially in 2026 should be treated with skepticism. Quality and safety can’t be verified for non-approved drugs.<\/p>\n The triple-agonist design balances GLP-1 and GIP effects (which lower blood sugar by improving insulin secretion and reducing appetite) against glucagon effects (which would raise blood sugar). In the phase 2 trial, patients with diabetes actually had improved glycemic control on retatrutide, suggesting the lowering effects dominate. Phase 3 trials in diabetic populations are providing more definitive data.<\/p>\n Possibly. The added glucagon mechanism provides a different pathway for weight loss (increased energy expenditure rather than just decreased intake). Some patients who plateau on tirzepatide may respond to retatrutide. Trial data on this specific question isn’t published yet.<\/p>\n Not exactly. Retatrutide is a single molecule engineered to activate all three receptors with specific affinity ratios. Combining tirzepatide with a separate glucagon drug wouldn’t replicate retatrutide’s pharmacology and isn’t a legitimate clinical approach.<\/p>\n Probably yes at launch, based on the typical pattern for newer obesity drugs. Pricing usually starts high and falls as competitors emerge or patents expire. Insurance coverage and direct cash programs typically take years to develop after launch.<\/p>\n It’s possible for many patients. Retatrutide’s 24% phase 2 weight loss is approaching sleeve gastrectomy territory (25% to 30%). If phase 3 confirms similar numbers and long-term durability holds with continued dosing, medication may displace surgery as first-line for many candidates with class II to III obesity.<\/p>\n Talk to your prescriber. For most patients, starting effective treatment now with available drugs is better than waiting. If retatrutide becomes available and offers a meaningful clinical advantage, switching is always an option.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" Tirzepatide is the best obesity drug currently approved. It produced 20.9% mean weight loss at 72 weeks in SURMOUNT-1 (Jastreboff et al.<\/p>\n","protected":false},"author":11,"featured_media":90836,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Tirzepatide vs Retatrutide: Dual vs Triple Agonist","_yoast_wpseo_metadesc":"Tirzepatide is the best obesity drug currently approved. It produced 20.9% mean weight loss at 72 weeks in SURMOUNT-1 (Jastreboff et al.","_yoast_wpseo_focuskw":"tirzepatide retatrutide","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[11],"tags":[],"class_list":["post-90837","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mounjaro"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90837"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90837\/revisions"}],"predecessor-version":[{"id":91970,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90837\/revisions\/91970"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/90836"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}How Much Weight Loss Has Retatrutide Produced?<\/h2>\n
When Will Retatrutide Be Available?<\/h2>\n
What About Side Effects?<\/h2>\n
What’s the Dosing?<\/h2>\n
What Does Each Cost?<\/h2>\n
Is Retatrutide Worth Waiting For?<\/h2>\n
How Does Retatrutide Compare on Cardiovascular and Other Outcomes?<\/h2>\n
FAQ<\/h2>\n
Can I Get Retatrutide Now?<\/h3>\n
How Is Glucagon Agonism Safe If Glucagon Raises Blood Sugar?<\/h3>\n
Will Retatrutide Work for Patients WHO Didn’t Respond to Tirzepatide?<\/h3>\n
Is Retatrutide Just Tirzepatide Plus Glucagon?<\/h3>\n
Will Retatrutide Be More Expensive Than Tirzepatide?<\/h3>\n
Could Retatrutide Replace Bariatric Surgery?<\/h3>\n
Should I Plan to Start with Retatrutide When It’s Available?<\/h3>\n